Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Kiromic BioPharma's Prioritizes New Gamma Delta T-Cell Product Candidate

  • Kiromic BioPharma Inc (NASDAQ:KRBP) has announced a strategic pipeline shift to prioritize its allogeneic, non-engineered off-the-shelf product candidate, Deltacel/KB-GDT.
  • Kiromic expects to submit its first new investigational new drug (IND) application to the FDA in 2H of 2022. 
  • The IND will seek to evaluate Deltacel in combination with a standard antitumor modality, with the expected beginning of trial activation by year-end. 
  • Related: Why Kiromic Biopharma Shares Are Skyrocketing Today?
  • Kiromic will also pursue INDs for its Procel and Isocel product candidates in combination with a standard antitumor modality in 2023.
  • These three additional IND filings will expand the Company's pipeline to five allogeneic GDT clinical trials and three product candidates.
  • Price Action: KRBP shares are up 14.60% at $0.46 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.